News

ny teaser oct 08

Read the latest update on who's doing what and where.

Print | Tell a friend

Clinical Trials Update provides you with latest news about clinical trials conducted by MVA members. The update gives insight to progress in studies, results and possible indications. As an MVA member please feel free to send us press releases for Clinical Trials Update at news@mva.org.

Read about the latest clinical trials below or use the archive in the bottom of the page to gain insight into past trials.

Week 41

Ofatumumab Induces Long Lasting Clinical Responses in Phase II RA Study

8 October - Genmab have announced that data showing that rheumatoid arthritis patients who participated in the ofatumumab (HuMax-CD20®) Phase II study achieved long lasting results at the 48 week follow up period. The data will be presented in a poster session at the ACR/ARHP 2008 Annual Scientific Meeting in San Francisco, California on October 26, 2008.

Bavarian Nordic Announces Positive Mature Phase II Results from Newly Acquired Prostate Cancer Vaccine

7 October - 125 patient, prospective randomized placebo-controlled phase II study shows statistically significant improved overall survival. Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC^TM that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US. The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after 4 years of follow-up show that patients receiving PROSTVAC^TM had a statistically significantly longer median overall survival by 8.5 months (p=0.015) compared to the control group.

Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

6 October - Biogen Idec along with Genentech have announced that a global Phase III study of Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for U.S. regulatory purposes.

Data From One-Year Liraglutide Phase 3 Study Published in The Lancet

25 September - Data from a 52-week phase 3 study (LEAD^TM 3) of liraglutide, a once-daily human GLP-1 analogue, were published today by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug. Moreover, the treatment with liraglutide leads to weight loss, reduced systolic blood pressure and lower rates of hypoglycaemia after 52 weeks of treatment.